In this ongoing phase 2 prospective study, we reported the short-term efficacy of neoadjuvant sintilimab (a PD-1 inhibitor) plus platinum-based chemotherapy in stage IIB-IIIB (excluding N3) EGFR-mutant NSCLC for stage I enrollment and showed that EGFR-mutant NSCLC could achieve comparable results through neoadjuvant immunotherapy plus chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.